Richard De Schutter elected chair of Durata
This article was originally published in Scrip
Durata Therapeutics has elected Richard DeSchutter chair of the company's board of directors. Mr De Schutter is also chair of Incyte Corporation, and was previously chair and CEO of DuPont Pharmaceuticals.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.